reactive arthritis: Reactive arthritis (ReA) is an autoimmune disorder belonging to the group of seronegative spondyloarthropathies and is characterized by the classic triad of arthritis, urethritis and conjunctivitis.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
232 |
4. Check minimum number of eventsNone |
232 |
5. Include endpointsNone |
232 |
6. Filter based on genotype QC (FinnGen only) |
217 |
Control definitions (FinnGen only)
- Control exclude
- RHEUMA_ARHTROPAT_REACTIVE
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M02
- Name in latin
- Morbus Reiter
Similar endpoints
↥List of similar endpoints to
Reiter disease
based on the number of shared cases.
Similar with more cases:
- Reactive arthropathies, FINNGEN
- Finngen Rheumatological endpoints
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1810 | 445 | 1350 |
| Only index persons | 1625 | 422 | 1203 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.01 | 0.04 |
| Only index persons | 0.04 | 0.02 | 0.05 |
| Median age at first event (years) | |||
| Whole population | 43.46 | 44.10 | 43.14 |
| Only index persons | 42.52 | 43.47 | 42.19 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 217 | 68 | 149 |
| Unadjusted period prevalence (%) | 0.05 | 0.02 | 0.07 |
| Median age at first event (years) | 42.80 | 38.66 | 44.70 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 223
- Matched controls
- 2230
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M02.3
ICD-10 Finland
Reiter disease
+∞
300.8
215
*
A07EC01
ATC
sulfasalazine; oral, rectal
35.2
160.2
125
78
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
22.3
125.7
126
123
L04AX03
ATC
methotrexate; systemic
13.8
79.2
94
112
L01BA01
ATC
methotrexate; systemic
25.5
74.4
56
29
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
16.8
73.1
70
59
M02.9
ICD-10 Finland
Reactive arthropathy, unspecified
278.0
62.6
61
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
13.2
56.0
61
62
L88
ICPC
Rheumatoid/seropositive arthritis
13.7
35.1
35
30
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
10.6
31.3
37
41
M45
ICD-10 Finland
Ankylosing spondylitis
13.2
30.7
31
27
M13.9
ICD-10 Finland
Arthritis, unspecified
7.3
29.2
49
83
P01BA02
ATC
hydroxychloroquine; oral
7.2
28.3
48
82
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
19.8
22.6
34
20
H02AB06
ATC
prednisolone; systemic
4.0
22.1
149
743
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
18.7
20.3
31
19
13603
ICD-8 Finland
Other and unspecified infective and parasitic diseases, Morbus Reiter, syndroma urethro-oculo-articularis
+∞
20.1
19
*
L04AA13
ATC
[U] leflunomide
21.1
19.2
28
15
S01BA01
ATC
dexamethasone; ophthalmic
9.0
19.2
25
31
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
7.9
19.1
28
40
M02.8
ICD-10 Finland
Other reactive arthropathies
206.7
18.8
19
*
H02AB07
ATC
prednisone; oral
4.5
18.3
52
140
L04AB01
ATC
etanercept; parenteral
27.3
15.0
20
8
0993A
ICD-9 Finland
Other venereal diseases, Reiter's disease
+∞
13.7
13
*
N48.1
ICD-10 Finland
Balanoposthitis
6.9
13.6
22
35
S01BA04
ATC
prednisolone; ophthalmic
18.7
12.8
19
11
ZX120
NOMESCO Finland
Intravenous
4.1
12.7
39
110
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
15.6
12.5
20
14
L04AB04
ATC
adalimumab; parenteral
12.7
12.1
21
18
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
21.4
11.3
16
8
S01FA02
ATC
scopolamine; ophthalmic
17.1
10.5
16
10
7111L
ICD-9 Finland
Arthropathy associated with infections, Arthropathy associated with Reiter's disease and nonspecific urethritis[UROARTHRITIS, USEAT NIVELET]
115.2
10.5
11
*
M02.1
ICD-10 Finland
Postdysenteric arthropathy
+∞
10.5
10
*
H20.1
ICD-10 Finland
Chronic iridocyclitis
24.8
10.4
14
6
S01CA02
ATC
prednisolone and antiinfectives; ophthalmic
21.2
9.9
14
7
L40.0
ICD-10 Finland
Psoriasis vulgaris
4.9
9.3
21
46
L40.5
ICD-10 Finland
Arthropathic psoriasis
13.3
9.0
15
12
M01AE03
ATC
ketoprofen; systemic, rectal
2.4
8.8
97
549
Z3231
NOMESCO Finland
Registered nurse
2.5
8.7
77
394
M13.0
ICD-10 Finland
Polyarthritis, unspecified
21.0
8.6
12
6
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
8.4
8.5
18
23
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
2.5
8.5
66
318
3640A
ICD-9 Finland
Disorders of iris and ciliary body, Acute and subacute iridocyclitis
93.4
8.5
9
*
M02.0
ICD-10 Finland
Arthropathy following intestinal bypass
+∞
8.4
8
*
J01MA02
ATC
ciprofloxacin; systemic
2.3
8.1
100
589
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.4
8.0
75
392
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.3
7.8
32
109
M01CB01
ATC
sodium aurothiomalate; parenteral
26.0
7.6
10
*
M01AB55
ATC
diclofenac, combinations; oral
4.1
7.4
21
55
L17
ICPC
Foot/toe symptom/complaint
2.3
7.2
76
415
71490
ICD-8 Finland
Other specified forms of arthritis, Arthritis postinfectiosa NUD
31.1
7.2
9
*
M01CB03
ATC
auranofin; oral
17.3
6.8
10
6
L04AA01
ATC
[U] ciclosporin
17.3
6.8
10
6
D07AD01
ATC
clobetasol; topical
2.6
6.7
44
194
D07XC01
ATC
betamethasone; topical
2.7
6.5
38
158
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.2
6.4
73
408
R4110
NOMESCO Finland
Physiotherapy
2.2
6.4
73
409
M01AH01
ATC
celecoxib; oral
2.4
6.3
47
220
M01AC06
ATC
meloxicam; systemic, rectal
2.0
6.2
93
577
M13.1
ICD-10 Finland
Monoarthritis, not elsewhere classified
10.4
6.1
11
11
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
2.7
6.1
35
144
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
26
49
5.87
13.60
1.9
1.2
—
—
—
0
0
170
1110
3.24
13.10
17.2
11.4
4.27
4.12
e9/l
0.33
152
971
28
64
4.86
11.82
1.4
1.4
2.00
0.02
iu/ml
—
5
12
34
95
4.04
11.13
1.5
2.5
1.70
5.80
iu/ml
—
9
26
94
534
2.31
8.33
2.9
2.8
345.76
357.32
umol/l
0.62
89
482
65
316
2.49
8.15
1.3
1.3
13.16
5.85
u/ml
0.37
24
125
189
1493
2.74
7.14
12.8
8.8
76.31
79.33
u/l
0.55
184
1418
65
356
2.17
5.99
1.3
1.3
26.20
29.21
iu/ml
0.10
21
108
141
1036
1.98
5.60
5.5
3.3
0.00
0.00
estimate
-0.00
44
227
22
73
3.23
5.55
1.3
1.3
—
—
—
0
0
140
1035
1.95
5.36
5.5
3.3
0.00
0.00
estimate
-0.00
43
227
86
541
1.96
5.35
4.4
3.0
0.23
0.32
e6/l
0.51
69
397
56
310
2.08
4.93
4.4
2.9
4.14
1.51
e6/l
0.58
31
158
115
819
1.83
4.73
5.8
7.1
1.21
1.21
mmol/l
0.54
110
766
139
1052
1.85
4.67
5.7
3.3
0.00
0.00
estimate
-0.00
42
210
40
198
2.24
4.65
1.7
1.9
—
—
—
0
0
17
55
3.26
4.46
2.7
1.5
—
—
—
0
0
190
1610
2.22
4.40
30.5
19.4
13.69
13.55
%
0.88
190
1598
42
224
2.08
4.04
1.8
2.0
—
—
—
0
0
121
917
1.70
3.69
6.2
8.4
1.21
1.20
mmol/l
1.00
110
799
29
145
2.15
3.28
2.7
2.8
70.06
66.38
ml/min/173m2
0.24
16
69
54
337
1.79
3.24
4.5
2.8
0.49
0.85
e6/l
1.11
29
181
208
1889
2.50
3.11
25.5
15.8
23.39
24.16
mg/l
0.13
190
1565
11
31
3.68
3.03
1.2
1.5
—
—
—
0
0
11
31
3.68
3.03
1.2
1.5
—
—
—
0
0
13
47
2.88
2.87
1.9
1.4
—
—
—
0
0
81
582
1.62
2.86
5.9
3.3
0.00
0.00
estimate
-0.00
41
210
25
125
2.13
2.84
4.1
9.4
23.26
24.79
mmol/l
1.55
25
125
81
598
1.56
2.49
4.8
2.8
0.00
0.01
estimate
0.80
34
186
7
16
4.48
2.49
3.9
4.3
3545.29
829.13
mg
—
7
16
25
132
2.01
2.48
5.6
11.5
93.04
93.26
%
0.06
25
132
33
192
1.84
2.47
4.0
3.1
—
—
—
0
0
12
46
2.70
2.40
1.1
1.3
—
40.75
—
0
6
103
815
1.49
2.24
5.3
3.2
0.00
0.00
estimate
-0.00
35
197
12
49
2.53
2.14
4.2
3.6
6.86
2.60
index
—
7
30
105
842
1.47
2.10
5.2
5.3
35.85
36.10
g/l
0.17
99
810
5
10
5.09
2.08
1.4
1.1
104.72
211.54
iu/ml
—
5
10
62
447
1.54
2.08
2.1
2.4
—
—
—
0
0
202
1868
1.86
2.00
22.7
15.0
87.12
84.16
ml/min/173m2
1.53
196
1731
37
240
1.65
1.92
3.1
2.9
4.79
7.62
umol/l
2.10
31
214
61
447
1.50
1.88
4.8
3.4
1.02
1.02
kg/l
0.25
37
299
145
1254
1.45
1.85
3.3
3.0
—
—
—
0
0
6
18
3.40
1.76
1.2
1.3
—
—
—
0
0
8
30
2.73
1.74
4.4
3.7
—
—
—
0
0
6
19
3.22
1.67
1.2
1.3
—
—
—
0
0
6
19
3.22
1.67
1.2
1.3
—
—
—
0
0
34
224
1.61
1.67
5.0
9.0
-0.12
0.74
mmol/l
0.52
26
189
103
850
1.39
1.65
2.6
2.8
—
—
estimate
—
0
0
5
14
3.63
1.62
1.0
1.0
—
—
—
0
0
10
43
2.39
1.61
2.0
1.6
—
—
—
0
0
20
115
1.81
1.58
2.8
1.7
—
—
—
0
0
97
797
1.38
1.58
2.3
2.1
94.63
93.24
pmol/l
0.14
57
426
6
21
2.91
1.51
1.0
1.0
—
—
—
0
0
42
299
1.50
1.48
5.7
7.4
104.79
104.05
mmol/l
0.47
42
299
6
22
2.77
1.44
1.2
1.3
—
—
—
0
0
10
46
2.23
1.42
1.6
1.5
—
—
—
0
0
9
41
2.24
1.38
2.2
1.5
—
—
—
0
0
5
17
2.98
1.36
1.0
1.1
—
—
—
0
0
10
49
2.09
1.24
1.2
1.2
483.60
236.57
u/ml
—
5
21
5
19
2.67
1.22
1.2
1.3
—
—
—
0
0
6
26
2.34
1.19
1.2
1.3
—
—
—
0
0
6
26
2.34
1.19
1.2
1.3
—
—
—
0
0
56
439
1.37
1.18
1.2
1.3
0.69
0.86
u/ml
0.47
14
124
0
33
0.00
1.17
0.0
1.4
—
—
—
0
0
56
440
1.36
1.16
1.9
1.7
0.78
1.44
mg/l
1.81
45
350
27
187
1.50
1.10
3.0
4.0
0.62
1.84
mmol/l
0.71
19
165
7
32
2.22
1.09
1.3
1.4
—
—
—
0
0
18
114
1.63
1.06
3.6
3.4
23.11
24.25
mmol/l
0.94
18
114
72
597
1.30
1.04
2.6
2.2
1071.44
169.84
u/l
0.47
63
568
98
848
1.28
1.01
2.0
2.0
1.41
1.46
mmol/l
0.27
86
712
11
61
1.84
1.00
1.4
1.3
—
—
—
0
0
9
50
1.83
0.98
1.3
1.5
572.44
197.84
e6/l
—
9
37
54
435
1.32
0.95
2.2
2.0
2.61
3.10
mg/l
1.03
45
384
98
855
1.26
0.93
3.5
2.9
227.56
161.30
ug/l
0.70
91
806
6
28
2.17
0.92
2.7
4.1
2.50
3.64
nmol/l
—
6
28
63
521
1.29
0.92
2.1
1.7
24.50
19.41
nmol/l
0.34
54
447
182
1715
1.33
0.89
4.7
4.8
1.72
1.90
mu/l
1.72
174
1573
130
1177
1.25
0.88
7.1
4.0
—
180.86
—
0
21
6
31
1.96
0.85
1.0
1.7
—
—
—
0
0
13
81
1.64
0.83
2.6
3.2
—
—
—
0
0
10
58
1.76
0.81
1.6
1.5
—
—
—
0
0
31
236
1.36
0.80
2.5
1.9
—
—
—
0
0
0
24
0.00
0.79
0.0
2.2
—
16.75
—
0
24
0
24
0.00
0.79
0.0
2.3
—
20.52
—
0
12
25
184
1.40
0.78
1.6
1.4
—
—
—
0
0
0
27
0.00
0.78
0.0
1.3
—
161.41
—
0
27
19
133
1.47
0.76
1.7
1.6
—
—
—
0
0
12
75
1.63
0.76
1.6
2.8
1.64
1.45
mg/l
0.25
12
69
70
600
1.24
0.76
2.7
2.9
0.53
0.74
ug/l
3.44
43
354
40
321
1.30
0.73
2.1
2.1
1.78
1.46
%
0.71
33
285
5
25
2.02
0.73
1.0
1.1
—
—
—
0
0
7
40
1.77
0.72
1.9
1.3
—
—
—
0
0
5
26
1.94
0.71
1.6
1.2
—
—
—
0
0
11
69
1.63
0.69
4.3
3.4
89.70
125.81
mg/l
0.16
11
58
11
69
1.63
0.69
4.3
3.4
29.49
32.46
mg/l
0.09
11
58
15
213
0.68
0.69
6.4
7.6
—
—
—
0
0
201
1940
1.37
0.66
21.9
18.0
139.80
139.73
mmol/l
0.16
201
1908
5
28
1.80
0.66
1.0
1.2
—
—
—
0
0
5
28
1.80
0.66
1.0
1.0
—
—
—
0
0
5
28
1.80
0.66
2.6
2.3
—
—
—
0
0
42
346
1.26
0.64
1.5
1.5
—
—
—
0
0
201
1944
1.34
0.61
22.0
18.2
3.97
3.99
mmol/l
0.55
201
1906
193
1857
1.29
0.61
4.8
4.9
5.82
5.98
mmol/l
1.62
185
1725
8
51
1.59
0.61
1.3
1.2
—
—
—
0
0
149
1397
1.20
0.61
3.9
3.9
14.74
14.78
pmol/l
0.08
141
1283
24
186
1.33
0.57
3.3
5.4
6.70
29.90
ug/l
0.51
19
154
15
107
1.43
0.57
1.6
1.4
—
—
—
0
0
6
37
1.64
0.56
1.0
1.2
—
—
—
0
0
155
1464
1.19
0.56
4.3
3.4
59.77
51.77
u/l
0.56
150
1393
31
251
1.27
0.55
2.5
1.8
—
—
—
0
0
6
38
1.59
0.54
1.2
3.3
—
1007.40
—
0
5
9
65
1.40
0.51
1.1
1.9
—
—
—
0
0
23
181
1.30
0.50
4.8
8.3
9.07
9.26
mmol/l
0.05
23
175
86
780
1.17
0.50
3.5
3.6
29.74
36.61
ng/l
0.29
54
537
13
93
1.42
0.49
1.0
1.0
—
—
—
0
0
7
47
1.50
0.48
2.1
8.3
—
150.38
—
0
8
41
350
1.21
0.47
4.2
3.7
131.29
353.74
ng/l
0.88
34
261
38
326
1.20
0.42
2.3
2.0
—
—
—
0
0
11
79
1.41
0.41
4.1
3.8
7.33
917.71
u/ml
—
6
66
0
15
0.00
0.41
0.0
1.0
—
40.54
—
0
8
0
15
0.00
0.41
0.0
1.0
—
565.50
—
0
8
0
17
0.00
0.41
0.0
1.6
—
—
—
0
0
5
34
1.48
0.40
1.2
1.5
—
—
—
0
0
5
79
0.62
0.36
1.6
1.8
3.98
5.30
mg/l
—
5
60
208
2041
1.28
0.36
29.4
20.0
79.33
80.70
umol/l
0.31
208
2024
15
118
1.29
0.34
1.8
1.8
0.27
0.34
mg/l
—
9
58
7
97
0.71
0.31
1.9
2.3
—
—
—
0
0
7
57
1.24
0.29
1.0
1.2
—
—
—
0
0
8
63
1.28
0.28
1.0
1.7
—
—
—
0
0
14
169
0.82
0.25
1.6
1.4
—
—
—
0
0
6
82
0.72
0.24
2.0
2.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
27.73
—
0
11
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.9
—
4.00
—
0
6
0
13
0.00
0.21
0.0
1.7
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
40
367
1.11
0.20
1.8
1.8
404.62
36562947.12
pmol/l
0.50
32
320
14
118
1.20
0.19
1.6
1.9
219.21
240.11
pmol/l
0.33
14
112
6
52
1.16
0.19
1.0
1.2
—
—
—
0
0
6
52
1.16
0.19
1.0
1.2
—
—
—
0
0
6
78
0.76
0.16
1.8
3.7
25.33
25.07
mmol/l
—
6
73
60
632
0.93
0.15
3.9
4.4
19.91
9.83
mg/mmol
0.39
45
426
9
82
1.10
0.15
1.0
1.3
—
—
—
0
0
27
252
1.08
0.10
2.0
2.1
3.92
3.66
ratio
0.42
20
198
6
54
1.11
0.09
1.2
1.4
—
—
—
0
0
6
70
0.85
0.08
2.3
2.6
26.92
24.38
mmol/l
—
6
70
101
989
1.04
0.07
4.3
4.7
1.66
2.10
ug/l
0.64
95
897
12
108
1.12
0.07
2.0
2.3
1.03
0.64
%
0.57
12
108
189
1874
1.06
0.07
4.3
4.4
1.37
1.36
mmol/l
0.09
182
1747
210
2088
1.10
0.06
36.6
23.4
91.85
90.99
fl
2.03
210
2069
9
103
0.87
0.06
1.2
1.1
1.33
1.48
g/l
—
9
103
210
2090
1.08
0.04
37.0
24.0
41.33
41.48
%
0.17
210
2069
80
788
1.02
0.03
3.9
4.1
23.71
22.21
%
0.33
35
339
210
2092
1.07
0.02
36.9
23.6
137.93
139.30
g/l
0.65
210
2071
61
600
1.02
0.02
2.9
3.2
1050.80
1025.31
ng/l
0.02
56
495
20
193
1.04
0.01
1.5
1.8
3.80
3.53
mmol/l
—
10
142
194
1945
0.98
0.00
5.2
5.1
1.39
1.37
mmol/l
0.24
189
1824
10
105
0.95
0.00
1.2
1.1
0.88
0.91
g/l
—
10
105
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
2.8
—
18.68
—
0
5
6
65
0.92
0.00
1.5
2.1
—
—
—
0
0
6
61
0.98
-0.00
1.2
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
90.83
—
0
6
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
8
80
1.00
-0.00
3.0
1.7
354.87
275.33
mu/l
—
8
74
0
9
0.00
-0.00
0.0
1.3
—
51.10
—
0
9
0
9
0.00
-0.00
0.0
2.4
—
43.67
—
0
9
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
76.01
—
0
8
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
20.96
—
0
8
0
8
0.00
-0.00
0.0
4.6
—
10.64
—
0
8
0
8
0.00
-0.00
0.0
4.6
—
4.70
—
0
8
Mortality – FinRegistry
↥Association
Association between endpoint REITER and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| REITER | 1.516 [1.12, 2.06] | 0.008 |
| Birth year | 0.999 [0.99, 1.01] | 0.892 |
During the follow-up period (1.1.1998 — 31.12.2019), 52 out of 387 females with REITER died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| REITER | 1.526 [1.28, 1.82] | < 0.001 |
| Birth year | 0.983 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 189 out of 1071 males with REITER died.
Mortality risk
Mortality risk for people of age
years, who have REITER.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.168% | 0.209% |
| 5 | 1.11% | 1.463% |
| 10 | 2.728% | 3.843% |
| 15 | 5.054% | 7.025% |
| 20 | 9.186% | 12.038% |
Relationships between endpoints
↥Index endpoint: REITER – Reiter disease
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data